Книга Пятый элемент здоровья. Как использовать менструальный цикл для поддержания жизненно важных функций организма - Лиза Хендриксон-Джек

“Polycystic ovary syndrome: not just a fertility problem.” Women’s Health. (2015): 433–436.

49. Dunaif, Andrea, and Bart C.J.M. Fauser. “Renaming PCOS – a two-state solution.” The Journal of Clinical Endocrinology & Metabolism 98, no. 11 (2013): 4325–4328; Rosenwaks, Zev. “Polycystic ovary syndrome, an enigmatic syndrome begging for a name change.” Fertility and Sterility 108, no. 5 (2017): 748–749.

50. Diamanti-Kandarakis, Evanthia, Jean-Patrice Baillargeon, Maria J. Iuorno, Daniela J. Jakubowicz, and John E. Nestler. “A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills.” The Journal of Clinical Endocrinology & Metabolism 88, no. 5 (2003): 1927–1932; de Melo, Anderson Sanches, Rosana Maria dos Reis, Rui Alberto Ferriani, and Carolina Sales Vieira. “Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits.” Open Access Journal of Contraception 8 (2017): 13–23.

51. Gordon, Catherine M. “Functional hypothalamic amenorrhea.” New England Journal of Medicine 363, no. 4 (2010): 365–371.

52. Chou, Sharon H., and Christos Mantzoros. “Bone metabolism in anorexia nervosa and hypothalamic amenorrhea.” Metabolism (2017).

53. Frisch, Rose E., and Janet W. McArthur. “Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset.” Science 185, no. 4155 (1974): 949–951.

54. Winkler, Laura Al-Dakhiel, Jacob Stampe Frølich, Maya Schulpen, and René Klinkby Støving. “Body composition and menstrual status in adults with a history of anorexia nervosa – at what fat percentage is the menstrual cycle restored?” International Journal of Eating Disorders 50, no. 4 (2017): 370–377.

55. Beals, Katherine A., and Amanda K. Hill. “The prevalence of disordered eating, menstrual dysfunction, and low bone mineral density among US collegiate athletes.” International Journal of Sport Nutrition and Exercise Metabolism 16, no. 1 (2006): 1–23.

56. Hobart, Julie A., and Douglas R. Smucker. “The female athlete triad.” American Family Physician 61, no. 11 (2000): 3357–3364.

57. Deimel, Jay F., and Bradley J. Dunlap. “The female athlete triad.” Clinics in Sports Medicine 31, no. 2 (2012): 247–254.

58. Ong, Jun Liang, and Iain A. Brownlee. “Energy expenditure, availability, and dietary intake assessment in competitive female dragon boat athletes.” Sports 5, 45, no. 2 (2017): 1–7.

59. Cialdella-Kam, Lynn, Charlotte P. Guebels, Gianni F. Maddalozzo, and Melinda M. Manore. “Dietary intervention restored menses in female athletes with exercise-associated menstrual dysfunction with limited impact on bone and muscle health.” Nutrients 6, no. 8 (2014): 3018–3039.

60. Biller, Beverly M.K., Howard J. Federoff, James I. Koenig, and Anne Klibanski. “Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea.” The Journal of Clinical Endocrinology & Metabolism 70, no. 2 (1990): 311–317.

61. Hergenroeder, Albert C. “Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults.” The Journal of Pediatrics 126, no. 5 (1995): 683–689.

62. Cann, Christopher E., Mary C. Martin, Harry K. Genant, and Robert B. Jaffe. “Decreased spinal mineral content in amenorrheic women.” JAMA 251, no. 5 (1984): 626–629.

63. Hergenroeder, Albert C. “Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults.” The Journal of Pediatrics 126, no. 5 (1995): 683–689.

64. Berger, Claudie, David Goltzman, Lisa Langsetmo, Lawrence Joseph, Stuart Jackson, Nancy Kreiger, Alan Tenenhouse, K. Shawn Davison, Robert G. Josse, Jerilynn C. Prior, and David A. Hanley. “Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis.” Journal of Bone and Mineral Research 25, no. 9 (2010): 1948–1957.

65. Hergenroeder, Albert C., E. O’Brian Smith, Roman Shypailo, Lovell A. Jones, William J. Klish, and Kenneth Ellis. “Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months.” American Journal of Obstetrics and Gynecology 176, no. 5 (1997): 1017–1025.

66. Warren, Michelle P., Jeanne Brooks-Gunn, Richard P. Fox, Claire C. Holderness, Emily P. Hyle, William G. Hamilton, and Linda Hamilton. “Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study.” Fertility and Sterility 80, no. 2 (2003): 398–404.

67. Altayar, Osama, Alaa Al Nofal, B. Gisella Carranza Leon, Larry J. Prokop, Zhen Wang, and M. Hassan Murad. “Treatments to prevent bone loss in functional hypothalamic amenorrhea: a systematic review and meta-analysis.” Journal of the Endocrine Society 1, no. 5 (2017): 500–511.

Глава 7

1. Wiley, T.S., Julie Taguchi, and Bent Formby. (2009). Sex, Lies, and Menopause: The Shocking Truth about Synthetic Hormones and the Benefits of Natural Alternatives. New York, NY: Harper Collins.

2. Watkins, E.S. “How the pill became a lifestyle drug: The pharmaceutical industry and birth control in the United States since 1960.” American Journal of Public Health 102, no. 8 (2012): 1462–1472.

3. Liao, Pamela Verma, and Janet Dollin. “Half a century of the oral contraceptive pill: historical review and view to the future.” Canadian Family Physician 58, no. 12 (2012): e757–e760.

4. Marsh, Margaret S., and Wanda Ronner. (2008). The Fertility Doctor: John Rock and the Reproductive Revolution. Baltimore, MD: Johns Hopkins University Press, 140.

5. Roberts, William C. “Facts and ideas from anywhere: ‘The pill’ and its four major developers.” Proceedings (Baylor University Medical Centre) 28, no. 3 (2015): 421–432.

6. Chasan-Taber, Lisa, Walter C. Willett, Meir J. Stampfer, Donna Spiegelman, Bernard A. Rosner, David J. Hunter, Graham A. Colditz, and JoAnn E. Manson. “Oral contraceptives and ovulatory causes of delayed fertility.” American Journal of Epidemiology 146, no. 3 (1997): 264.

7. Lefebvre, Yves. “Anatomical and functional changes induced by oral contraception.” Canadian Medical Association Journal 102, no. 6 (1970): 622.

8. Korver, Tjeerd, Christine Klipping, Doris Heger-Mahn, Ingrid Duijkers, Gonnie van Osta, and Thom Dieben. “Maintenance of ovulation inhibition with the 75-μg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12– h delays in tablet intake.” Contraception 71, no. 1 (2005): 8–13; Rice, C.F., S.R. Killick, T. Dieben, and H. Coelingh Bennink. “A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily.” Human Reproduction 14, no. 4 (1999): 982–985; Xiao, Bilian, Liying Zhou, Xuling Zhang, Tapani Luukkainen, and Hannu Allonen. “Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device.” Contraception 41, no. 4 (1990): 353–362.

9. Xiao, Bilian, Tao Zeng, Shangchun Wu, Hongzhu Sun, and Na Xiao. “Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term